| Literature DB >> 36127085 |
Tengfei Yang1, Bo Zhao2, Xuelai Guan3, Dongmei Pei4.
Abstract
OBJECTIVE: The purposes of current research were to investigate the time-dependent dynamic alteration of white cell count (WCC) in health management populations and to analyse its association with the type 2 diabetes mellitus (T2DM).Entities:
Keywords: epidemiology; general diabetes; quality in health care
Mesh:
Year: 2022 PMID: 36127085 PMCID: PMC9490632 DOI: 10.1136/bmjopen-2021-057966
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Figure 1Flow chart of records that were excluded from the physical examination database.
Figure 2Four WCC trajectories under the best-fit model in 2016–2019. WCC, white cell count.
Baseline characteristics according to WCC trajectory
| Variables | Total | Trajectory 1 | Trajectory 2 | Trajectory 3 | Trajectory 4 | P value |
| Age | 40 (34–54) | 45 (36–56) | 40 (34–52) | 39 (34–52) | 38 (34–48.25) | <0.01 |
| Sex | <0.01 | |||||
| Men | 2849 | 579 | 1362 | 723 | 185 | |
| Women | 5075 | 1602 | 2302 | 1018 | 153 | |
| Total protein (g/L) | 70.4 (67.7–73.3) | 69.8 (67.2–72.8) | 70.6 (67.8–73.2) | 70.7 (68.1–73.8) | 70.6 (68.1–73.9) | <0.01 |
| Albumin (g/L) | 46.1 (44.3–47.8) | 46 (44.3–47.6) | 46.1 (44.3–47.9) | 46.1 (44.2–47.9) | 46.1 (44.3–48) | 0.22 |
| Albumin to globulin ratio | 1.89 (1.7–2.11) | 1.92 (1.73–2.14) | 1.9 (1.71–2.11) | 1.86 (1.66–2.06) | 1.86 (1.69–2.07) | <0.01 |
| Aspartate aminotransferase (U/L) | 24 (20–28) | 23 (20–27) | 23 (20–27) | 24 (20–28) | 24 (21–30) | <0.01 |
| Alanine aminotransferase (U/L) | 24 (19–32) | 22 (18–29) | 24 (19–32) | 26 (19–36) | 29 (21–42.25) | <0.01 |
| γ-glutamate transpeptidas (U/L) | 18 (13–29) | 16 (12–23.5) | 18 (13–29) | 21 (14–34.5) | 27 (17–45.25) | <0.01 |
| Total bilirubin (umol/L) | 12.6 (9.9–16) | 12.9 (10.3–16.3) | 12.7 (10.1–16) | 12.2 (9.4–15.75) | 11.9 (9.1–15.03) | <0.01 |
| Direct bilirubin (umol/L) | 4 (2.9–5.2) | 4.1 (3–5.2) | 4 (3–5.2) | 3.8 (2.8–5.1) | 3.8 (2.6–4.9) | <0.01 |
| Total bile acid (umol/L) | 2.33 (1.35–3.98) | 2.33 (1.34–3.89) | 2.3 (1.38–3.97) | 2.41 (1.3–4.12) | 2.25 (1.45–3.89) | 0.69 |
| White cell count ×109/L | 6.4 (5.4–7.5) | 5 (4.4–5.5) | 6.4 (5.8–7) | 7.9 (7.3–8.7) | 9.9 (9.1–11) | <0.01 |
| Red cell count ×109/L | 4.76 (4.47–5.13) | 4.63 (4.36–4.95) | 4.78 (4.48–5.14) | 4.88 (4.58–5.22) | 5.03 (4.68–5.38) | <0.01 |
| Platelet count ×109/L | 230 (198–265) | 212 (184–242) | 231 (201–264) | 246 (214–283) | 266 (233.75–304.75) | <0.01 |
WCC, white cell count.
Figure 3Distribution of incidence rate of T2DM by two different grouping methods. T2DM, type 2 diabetes mellitus; WCC, white cell count.
Cox proportional hazards model of the WCC trajectory, baseline WCC quartile and type 2 diabetes onset
| New-cases/total (n) | Incidence density (%) | Model 1 | Model 2 | Model 3 | |
| WCC trajectory | |||||
| Trajectory 1 | 48/2181 | 2.2 | 1 | 1 | 1 |
| Trajectory 2 | 96/3664 | 2.62 | 1.19 (0.84–1.69)* | 1.26 (0.89–1.79)* | 1.2 (0.84–1.71)* |
| Trajectory 3 | 80/1661 | 4.82 | 2.1 (1.47–3.01) | 2.14 (1.49–3.08) | 1.94 (1.32–2.83) |
| Trajectory 4 | 25/338 | 7.4 | 3.42 (2.11–5.55) | 3.64 (2.22–5.97) | 3.08 (1.82–5.21) |
| Baseline WCC (quartile) | |||||
| Q1 (<5.4) | 44/2083 | 2.11 | 1 | 1 | 1 |
| Q2 (5.4–6.4) | 58/2080 | 2.79 | 1.32 (0.89–1.96)* | 1.26 (0.85–1.87)* | 1.16 (0.78–1.73)* |
| Q3 (6.40–7.5) | 64/1801 | 3.55 | 1.69 (1.15–2.48) | 1.56 (1.06–2.29) | 1.43 (0.96–2.13)* |
| Q4 (>7.5) | 83/1960 | 4.23 | 2.02 (1.4–2.91) | 2.04 (1.41–2.96) | 1.68 (1.13–2.5) |
Model 1: Unadjusted.
Model 2: adjusted for age, sex.
Model 3: adjusted for model 2 plus total protein, aspartate aminotransferase level, alanine aminotransferase level, γ-glutamyl transpeptidase level, total bilirubin level, direct bilirubin level, red cell count and platelet count.
*p>0.05, baseline WCC (quartile): Quartile grouping of WCC at the first physical examination.
WCC, white cell count.